MARK MERRELL: Open Payments
NPI 1922342377 · MERIDIAN, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$402 in 22 payments from 15 companies in 2025. Trend: 2023 $396 · 2024 $73 · 2025 $402
Food & beverage: $402
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 5 | $91 |
| Lilly USA, LLC | 2 | $50 |
| Axsome Therapeutics, Inc. | 2 | $38 |
| Insulet Corporation | 1 | $28 |
| VERTEX PHARMACEUTICALS INCORPORATED | 1 | $25 |
| Astellas Pharma US Inc | 1 | $23 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $21 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $20 |
| E.R. Squibb & Sons, L.L.C. | 1 | $19 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $19 |
Products named: MOUNJARO, Rybelsus, Wegovy, Omnipod, JOURNAVX, Veozah, JARDIANCE, Symbravo.
Industry payments across ID — which companies pay providers there.
